BeiGene announces clinical results of anti-PD-1 antibody- Tislelizumab
Category: #health  | By Mateen Dalal  | Date: 2019-09-23 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

BeiGene announces clinical results of anti-PD-1 antibody- Tislelizumab

With novel clinical trials, organizations across the world are developing new therapies and next-generation treatment for targeting fatal diseases such as cancer. The result of such clinical trials can aid the improvement in existing treatments and give patients hope for a better future.

BeiGene Ltd. is one such commercial-stage biopharmaceutical company that develops and commercializes immuno-oncology drugs and innovative molecularly-targeted for cancer treatment. Recently, the firm has announced its clinical results on investigational anti-PD-1 antibody Tislelizumab from 3 ongoing trials in China.

Reportedly, these results were presented at 22nd Annual Meeting of CSCO (Chinese Society of Clinical Oncology) held in Xiamen, China. Apart from this, the company also presented additional four poster presentations on pamiparib, tislelizumab, and zanubrutinib.

According to Yong (Ben) Ben, Chief Medical Officer, M.D., Immuno-Oncology at BeiGene, said that the data shows the potential of tislelizumab to benefit patients in cancer treatment, specially to fulfill an unmet need in China and around the world.

He said that, in anticipation of the company’s first regulatory approvals in China for tislelizumab in urothelial carcinoma and Hodgkin’s lymphoma, their firm is approaching the 1st stage completion on the cutting-edge biologics manufacturing facility, which will be a model for quality biologics manufacturing operations.

Incidentally, the company’s announced results of the Phase 2 trial of tislelizumab were also in combination with chemotherapy as first-line treatment for an advanced lung cancer patient in China.

About BeiGene

BeiGene is a research-based, commercial-stage, commercial-stage biotechnology focusing on immuno-oncology and molecularly targeted cancer therapeutics. The company is working to create combination solutions that aim to have both lasting and meaningful impact on cancer treatment.

With a team around 2,700 employees in China, Australia, Europe, and the United States, the company is working towards developing novel oral small molecules and monoclonal antibodies for treating cancer.

Some drugs that BeiGene markets include REVLIMID® (lenalidomide), ABRAXANE® (nanoparticle albumin-bound paclitaxel), and VIDAZA® (azacitidine) under a license from Celgene Corporation in China.

 Source Credit -https://www.globenewswire.com/news-release/2019/09/22/1918784/0/en/BeiGene-Announces-Clinical-Results-on-Tislelizumab-Presented-at-the-22nd-Annual-Meeting-of-the-Chinese-Society-of-Clinical-Oncology-CSCO.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...